ALFA Finder| Revenue growth | FY26 Consol 12.3%; FY27 Guide 22.7% to 28% growth. |
|---|---|
| Margins | Standalone EBITDA 26.8%; Consol 23-25% expected due to acquisitions. |
| Demand visibility | Intact; pending orders in hand despite logistics nightmares. |
| Management confidence | Strong; cite 15-20 year customer relationships and 399 patents. |
Growth
FY26 Consolidated revenue up 12.3%; Q4 standalone revenue grew 5.2% YoY and 6% sequentially.
Outlook
FY27 consolidated revenue guidance of ₹2,300-2,400cr (25%+ growth). Planned FY27 capex of ₹200-225cr.
Risks
High raw material costs (crude-linked), logistics bottlenecks in West Asia, and Chinese dumping in Renal segment.
Earnings Call filed with BSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,672.10
- Market cap
- ₹16,949 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 53.2×Sector 54.5×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Earnings Call Transcript: Key Takeaways
Consolidated Q2 revenue rose 31%, but H1 organic growth was only 14%. Pendra Care is loss-making and Italy tenders are delayed. FY27 revenue guidance was reaffirmed and the standalone margin band raised.
- Call
- Guides 100% growth
Poly Medicure Other Announcement
Poly Medicure's board revised five governance policies and codes, including material subsidiary, materiality, related party transactions, and insider trading codes. The revised documents are published on the company website.
Poly Medicure Q2 FY27 Results: Net Profit ₹95.1 Cr, Up 3.6% YoY
Poly Medicure Ltd reported revenue from operations of ₹580.5 Cr (+30.8% YoY) and net profit of ₹95.1 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹95.1 Cr · +3.6% YoY
Poly Medicure Board Meeting Date
Poly Medicure will hold a board meeting on 05 November 2026 to consider unaudited results. Trading window stays closed until 07 November 2026.
Poly Medicure Other Announcement
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.